Kymera Therapeutics Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $39.2M | $47.1M | $78.6M | $46.8M | $72.8M | $34.0M | $2.9M |
| Cost of Revenue | $39.2M | $47.1M | $78.6M | $46.8M | — | — | — |
| Gross Profit | $0 | $0 | $0 | $0 | — | — | — |
| Gross Margin | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — |
| Operating Expenses | |||||||
| Research & Development | $316.6M | $240.2M | $189.1M | $164.2M | $137.0M | $62.1M | $37.2M |
| SG&A Expense | $68.2M | $63.5M | $55.0M | $43.8M | $36.3M | $18.2M | $8.0M |
| Operating Income | $-349.4M | $-261.6M | $-165.5M | $-161.3M | $-100.5M | $-46.3M | $-42.2M |
| Operating Margin | -891.1% | -555.8% | -210.6% | -344.4% | -138.0% | -136.1% | -1,438.5% |
| Interest Expense | — | — | — | — | — | — | — |
| Pretax Income | $-311.4M | — | — | — | — | — | — |
| Income Tax Expense | $0 | — | — | $0 | $0 | $0 | $0 |
| Net Income | $-311.4M | $-223.9M | $-147.0M | $-154.8M | $-100.2M | $-45.6M | $-41.2M |
| Net Margin | -794.0% | -475.6% | -187.0% | -330.6% | -137.6% | -134.0% | -1,405.8% |
| EPS (Basic) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.05 | $-8.09 |
| EPS (Diluted) | $-3.69 | $-2.98 | $-2.52 | $-2.87 | $-2.09 | $-1.05 | $-8.09 |
| Shares Outstanding (Basic) | 84.5M | 75.0M | 58.4M | 53.9M | 48.0M | 52.0M | 5.8M |
| Shares Outstanding (Diluted) | 84.5M | 75.0M | 58.4M | 53.9M | 48.0M | 52.0M | 5.8M |
| Dividends Per Share | — | — | — | — | — | — | — |